-+ 0.00%
-+ 0.00%
-+ 0.00%

What Investors Got Wrong About Raia Drogasil Before The Drop

Simply Wall St·11/15/2026 16:18:43
Listen to the news

Investors who held Raia Drogasil from the start of the year are down 38.8%, including dividends. If you had committed fresh capital on 1 January 2026, that outcome would be hard to square with Q3 2026 results showing higher revenue and net income than a year earlier. So what did the original bullish and bearish cases miss about digital execution, store expansion, and aging demographics that could reasonably explain this gap between thesis and return?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

If the move has made Raia Drogasil harder to judge, start where the gap is still open and scan 196 high quality undervalued stocks.

The Two Stories Investors Had To Weigh On Raia Drogasil

The shares cost R$23.4 at the start of the period, and anyone looking at Raia Drogasil then had two very different stories to weigh.

On the optimistic side, the June 2025 Narrative put Fair Value at R$31, based on rapid digital sales growth, AI driven personalisation, a scaling marketplace and Brazil's aging population feeding more pharmacy demand.

The December 2025 bear Narrative set Fair Value at R$21.58, assuming revenue growth of 14.0%, a 3.4% profit margin, but also warning that rising competition and regulatory changes could pressure pricing and earnings.

BOVESPA:RADL3 Trailing 12-Month Earnings & Revenue History as at Nov 2026
BOVESPA:RADL3 Trailing 12-Month Earnings & Revenue History as at Nov 2026

What The Results Changed For Raia Drogasil

Q3 2026 put hard numbers on both stories. Raia Drogasil reported revenue of R$11,409.006m and net income of R$408.262m, up from R$10,580.432m and R$361.764m a year earlier. Net margin moved from 3.4% to 3.6%, which supported both the bullish and cautious narratives that assumed at least mid single digit profitability. The quarter therefore did not settle the argument.

The lesson is simple. When a thesis leans on margin improvement, treat the reported net margin as the key line to track and test every upbeat story against that figure each quarter.

What Raia Drogasil's Lower Price Now Asks You To Believe

Raia Drogasil trades at R$14.29 from the start of the year, after a total return loss of 38.8%. The bearish analyst Narrative on Simply Wall St still places its Fair Value above that level, based on how digital scale and GLP-1 exposure might translate into future earnings power.

The same Narrative stresses that this depends on omnichannel reach turning into strong cash generation without SG&A and personnel costs eating into margins. This is the key execution assumption a buyer at today's price needs to test.

"The main thing that has to go right is that Raia Drogasil converts its large omnichannel scale, rapid delivery, and expanding GLP-1 category into sustained cash generation while keeping SG&A and personnel costs under control."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Raia Drogasil And Another Aging Bet

Raia Drogasil leans on aging demographics and recurring healthcare needs. You could also look at where those same patients turn next.

Many older households look beyond prescriptions to fertility help for their adult children. That points to a different healthcare provider built around assisted reproduction.

This business runs specialist clinics, performs procedures like egg freezing, and supports cross border patients. It has been rolling out new centres across several Asian markets.

Expansion spending affects short term earnings, yet builds capacity and reach. The open question is how those new clinics fill over time.

Could this be another way into the opportunity? → Explore the healthcare AI opportunity and its 38% discount to one Narrative's Fair Value